Olaparib (300 mg BID)

DRUG3 trials

Sponsors

Centre Leon Berard, Gustave Roussy, Cancer Campus, Grand Paris, Peter MacCallum Cancer Centre, Australia

Conditions

Endometrial CancerMalignant Solid NeoplasmsMetastatic Castrate Resistant Prostate Cancer (mCRPC)p53abn

Phase 1

Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer

Not yet recruitingNCT07090369

Peter MacCallum Cancer Centre, AustraliaMetastatic Castrate Resistant Prostate Cancer (mCRPC)

Start: 2025-11-01End: 2028-12-01Target: 20Updated: 2025-07-29

Phase 2

Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment

RecruitingNCT02029001

Centre Leon BerardMalignant Solid Neoplasms

Start: 2014-03-31End: 2027-10-31Target: 900Updated: 2025-08-07

Phase 3

Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for p53abn Endometrial Cancer

RecruitingNCT06712472

Gustave Roussy, Cancer Campus, Grand ParisEndometrial Cancer, p53abn

Start: 2024-06-26End: 2031-12-01Target: 554Updated: 2026-01-20

Related Papers

Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort

Cancers2023-06-302 citations

Durvalumab + tremelimumab in biologically selected advanced/metastatic solid tumors.

Journal of Clinical Oncology2023-06-01

Correlation between an automated functional assay that predicts targeted agent (TA) sensitivity and the tumor response of the sorafenib treatment evaluated within the MOST clinical trial

Annals of Oncology2018-09-01

MEVITEM: A European, randomized, open-label Phase I/II of vismodegib in combination with temozolomide versus temozolomide alone in adult patients with recurrent/ refractory medulloblastoma presenting an activation of the Sonic Hedgehog pathway.

Journal of Clinical Oncology2016-05-202 citations

A randomized, open-label, Phase II trial evaluating the clinical benefit of a maintenance treatment targeting tumor molecular alterations in patients with advanced solid tumors.

Journal of Clinical Oncology2015-05-201 citations